Weight loss medications over the years: a history of safe medical obesity treatments

Posted on June 18, 2024 by Sally-Anne Turner

It feels like recently we've been hearing constant news, praise, and scientific discoveries in regard to medical weight loss. Be that the birth of Ozempic and its active ingredient semaglutide totally changing the game for obesity treatment or the growing interest in tirzepatide, dual-acting medications like Mounjaro, weight loss medication has well and truly exploded in the medical world. The conversation around these treatments has shifted dramatically from niche medical interventions to mainstream healthcare solutions that are being discussed in homes, workplaces, and medical practices across the United Kingdom.

Obesity has been creating health problems for millions of people around the world for years, and in the United Kingdom we've been topping the charts in Europe for our alarmingly high population of obese adults. The birth of GLP-1 weight loss injections catapulted medical weight loss interventions into the conversation in 2022, but doctors and clinical researchers have been exploring ways to solve the obesity crisis for decades. What many people don't realise is that the journey to today's breakthrough medications has been long, complex, and marked by both significant successes and important lessons about patient safety and the need for comprehensive clinical support.

Medical treatments for obesity have been available for some time and, when paired with clinical support, have been seen to produce incredible weight loss results, changing the lives of many. As a matter of fact, Bodyline Clinic has been treating those living with obesity and weight-related health complications with medical weight loss treatments for over 17 years. Throughout this time, we've witnessed firsthand the evolution of weight loss medications, from the early appetite suppressants to today's sophisticated hormone-based therapies that work with the body's natural regulatory systems rather than against them.

Starting out in clinics dotted around the northwest of England and developing into remote clinical services for patients around the country, we are equipped with a wealth of clinical expertise in the medical weight loss field. Our team of experienced doctors and nurse prescribers have supported over 100,000 patients through their weight loss journeys, adapting our treatment protocols as new medications have become available and as our understanding of obesity as a complex medical condition has deepened. This extensive experience has taught us that medication alone is never the complete answer – sustainable weight loss requires a holistic approach that addresses nutrition, physical activity, psychological factors, and long-term habit formation.

In this article, we'll be delving into the history of weight loss medications, from oral tablets to dual-acting GLP-1 and GIP injections, and discussing the measures clinical providers such as ourselves must take to ensure safe and effective weight loss when treating obesity medically. We'll explore how each generation of medication has built upon the lessons of the previous one, how regulatory frameworks have evolved to protect patients, and what the future might hold for medical weight loss treatment. Understanding this history is crucial for anyone considering medical weight loss treatment, as it provides context for why certain protocols exist and why working with regulated, experienced providers matters so much.

The near impossible fight against obesity

The attempt to combat obesity and its related weight health problems is a global one. In fact, the prevalence of obesity has tripled from 1975 to 2022 and is estimated to impact over one billion people worldwide, according to the World Obesity Federation. This staggering increase represents one of the most significant public health challenges of our time, with implications that extend far beyond individual health to affect healthcare systems, economies, and societies as a whole. The rapidity of this increase suggests that obesity is not simply a matter of individual choice or willpower but rather a complex condition influenced by environmental, genetic, social, and physiological factors.

For reference, obesity is usually defined as having a body mass index (BMI) of 30 or above. BMI between 25 and 30 is classified as 'overweight'. You can calculate your BMI using online calculators, though it's important to bear in mind that BMI is a controversial tool for measuring weight health. While BMI provides a useful population-level screening tool, it doesn't account for muscle mass, bone density, body composition, or distribution of fat. Nevertheless, it remains the most widely used metric in clinical practice for assessing weight-related health risks, and the categories of overweight and obesity as defined by BMI have been consistently associated with increased health risks across numerous large-scale studies.

In the UK, the problem is magnified, particularly as our health services are nationalised. The Health Survey for England 2021 estimated that 25.9% of adults in England are obese and a further 37.9% are overweight but not obese. This means that nearly two-thirds of the adult population in England carries excess weight, placing enormous strain on the NHS and contributing to the development of numerous chronic conditions that require ongoing medical management. The economic cost of obesity to the UK is estimated at billions of pounds annually when considering direct healthcare costs, lost productivity, and early mortality.

Obesity can lead to a multitude of physical and mental health problems. The risk of the development of medical conditions such as heart disease, diabetes, high blood pressure, and certain types of cancer all increases in people living with obesity. Beyond these well-known conditions, obesity is also associated with sleep apnoea, fatty liver disease, osteoarthritis, reproductive health issues, and increased risk of complications from surgery and anaesthesia. The psychological impact should not be underestimated either – people living with obesity often face stigma, discrimination, and reduced quality of life, which can contribute to depression, anxiety, and social isolation.

One shocking fact that research has now shown is that obesity has a greater link to cancer risk than smoking, being attributed to be the underlying cause in up to 8% of all cancer cases. This statistic often surprises people, as the cancer risks associated with smoking have been so effectively communicated through public health campaigns. However, the relationship between obesity and cancer is complex and involves multiple mechanisms, including chronic inflammation, hormonal changes, and metabolic dysfunction.

Obesity can be the cause of cancer in the liver, gallbladder, bowel, breasts, kidney, and pancreas, to name a few, all with a high enough risk of mortality when caught at later stages. Additionally, obesity is linked to increased risk of oesophageal cancer, endometrial cancer, ovarian cancer, and certain types of blood cancers. The mechanisms by which obesity increases cancer risk include increased levels of insulin and insulin-like growth factors, chronic low-grade inflammation, altered sex hormone metabolism, and changes in the gut microbiome. Understanding these connections helps explain why weight loss can have such profound effects on overall health and disease risk reduction.

With that sobering fact, it can be tempting to say that people just need to eat less and move more and that will solve our problems. This oversimplified approach has dominated public health messaging for decades, yet obesity rates have continued to climb. This paradox suggests that the "eat less, move more" paradigm, while containing a kernel of truth, fundamentally misunderstands the complexity of weight regulation and the multiple factors that influence body weight.

Well, yes, in a very simplistic and rudimentary sense, eating less and moving more can help people lose weight and potentially reduce their risk of obesity-related health risks. But it's just not that simple. The human body is not a simple machine that responds predictably to caloric input and output. Our weight is regulated by an incredibly complex system involving multiple hormones, neurotransmitters, and metabolic pathways that evolved over millions of years to protect us from starvation. When we lose weight, our body responds by increasing hunger hormones, decreasing satiety hormones, and reducing metabolic rate – all designed to drive weight back up to our previous "set point". This is why studies consistently show that the vast majority of people who lose weight through diet and exercise alone regain it within a few years.

There are so many factors that can impact a person's ability to combat obesity. Some people are more likely to be obese due to genetics, medical history, or hormonal imbalances going unnoticed, making it very difficult for them to lose weight with diet and exercise alone. Genetic factors are estimated to account for 40-70% of the variation in body weight between individuals. Certain genetic variants affect how efficiently we store fat, how hungry we feel, how satisfied we feel after eating, and how our bodies respond to different types of food. Medical conditions such as hypothyroidism, polycystic ovary syndrome, Cushing's syndrome, and certain medications can also contribute to weight gain and make weight loss more difficult.

All this, and not mentioning culture, ethnicity, lifestyle, and job roles, each impacting our predisposition to weight gain. Socioeconomic factors play a significant role, with obesity rates generally higher in areas of greater deprivation where access to healthy food may be limited and safe spaces for physical activity may be scarce. Shift work disrupts circadian rhythms and has been associated with increased obesity risk. Stress and lack of sleep both affect hormones that regulate appetite and metabolism. Cultural attitudes towards food, body size, and physical activity all influence weight-related behaviours. The built environment – whether neighbourhoods are walkable, whether healthy food is accessible and affordable – shapes the choices people can realistically make.

Fundamentally, the world as we know it with easy access to processed food, paired with the fact that evolutionarily we are not wired to lose weight, obesity is incredibly difficult to fix and then maintain; we can lose weight, but so often we just put the weight back on again. Our modern food environment, characterised by hyperpalatable foods engineered to override our natural satiety signals, constant food availability, and large portion sizes, is fundamentally mismatched with our evolutionary biology. Our ancestors faced periods of food scarcity and needed to be able to store energy efficiently when food was available. Today, in an environment of constant food abundance, these once-adaptive mechanisms contribute to obesity. This is why medical interventions that work with our biology rather than simply relying on willpower have become so important in addressing the obesity crisis.

Extreme measures for weight loss

In 2002, the UK's National Institute for health and Care Excellence (NICE) first advocated the use of bariatric surgeries as treatment for morbidly obese patients. This represented a significant shift in the medical approach to obesity, acknowledging that for some patients with severe obesity, conventional diet and exercise interventions were insufficient and more intensive medical intervention was warranted. Bariatric surgery had been performed for decades prior to this, but the NICE guidance provided a framework for when such surgery should be considered and what support patients should receive.

Bariatric surgeries include gastric band surgery, gastric bypass surgery, or gastric sleeve surgery. They work by altering the digestive system, essentially shrinking the stomach to reduce the number of calories a person can consume. Each type of surgery works through slightly different mechanisms. Gastric banding involves placing an adjustable band around the upper part of the stomach to create a small pouch, restricting the amount of food that can be eaten at one time. Gastric bypass creates a small stomach pouch and reroutes the small intestine, reducing both the amount of food that can be eaten and the calories absorbed. Gastric sleeve surgery involves removing a large portion of the stomach, leaving a tube-shaped stomach that holds much less food and produces less of the hunger hormone ghrelin.

Bariatric interventions on the NHS are only performed on individuals with a BMI of over 40, or over 35 with weight health related problems. Patients must also demonstrate that they have tried and failed to lose weight through conventional methods and must be prepared to make significant lifestyle changes following surgery. The assessment process is thorough and typically involves psychological evaluation, nutritional counselling, and medical optimisation before surgery is approved. This careful gatekeeping is necessary because bariatric surgery, while effective, carries significant risks and requires lifelong commitment to dietary changes and vitamin supplementation.

These surgeries are often successful when done safely. In England, on average, 6500-7000 procedures are performed annually and tend to result in weight loss of 20-30% of the patient's initial weight. The weight loss is sustained if patients develop healthy habits and continue to seek support from their consultant beyond the surgery. Long-term studies have shown that bariatric surgery can lead to remission or improvement in type 2 diabetes, reduction in cardiovascular risk factors, improved quality of life, and reduced mortality compared to non-surgical treatment of severe obesity. However, success is highly dependent on patient adherence to post-surgical dietary guidelines, attendance at follow-up appointments, and commitment to lifestyle changes.

However, with Turkey's surgery culture of more lax requirements and cheaper private costs, there has been an increase in people from the UK who do not fit the NHS's requirements for gastric surgery flying to Turkey and getting it performed there. The appeal is understandable – procedures that might cost £10,000-£15,000 privately in the UK can be obtained for a fraction of that cost abroad, and the eligibility criteria are often much less stringent. However, this comes with significant risks that are not always apparent to patients making these decisions.

This can be very dangerous and has resulted in deaths and severe complications on return to the UK. Doctors are reporting very unwell patients regularly landing at UK airports on flights from Turkey and having to be taken straight to hospital. Complications can include severe infections, internal bleeding, blood clots, anastomotic leaks (where surgical connections don't heal properly), and nutritional deficiencies. When complications occur abroad, patients may not receive adequate follow-up care, and language barriers can make it difficult to understand post-operative instructions. When they return to the UK, NHS surgeons are often faced with trying to manage complications from procedures they didn't perform, without access to the original surgical notes or details of the techniques used.

Turning to gastric surgery for weight loss should always be last resort and done with the supervision of a doctor and surgeon who can treat you before, during, and long after a procedure. The importance of comprehensive pre-operative assessment, skilled surgical technique, and long-term follow-up care cannot be overstated. This is why many patients and healthcare providers are increasingly interested in medical weight loss options that can achieve significant results without the risks and irreversibility of surgery. The emergence of highly effective weight loss medications has provided new options for patients who might previously have considered surgery as their only hope for substantial weight loss.

The little pink pill

Phentermine, also known as the 'pink pill', was first introduced in the United States in 1959 as a treatment for obesity. The oral tablet is a centrally acting appetite suppressant that works in the appetite centre of the brain to reduce calorie intake. Phentermine belongs to a class of medications called sympathomimetic amines, which work by stimulating the release of neurotransmitters in the brain, particularly norepinephrine. This increased norepinephrine activity reduces hunger signals and can also provide a mild increase in energy expenditure, making it easier for patients to maintain a calorie deficit necessary for weight loss.

The medication is only prescribed by registered clinicians for the short-term treatment for obesity and is to be taken in three-month bursts in combination with a reduced-calorie diet and exercise. Phentermine is only available with a prescription from a registered clinician and is not recommended for long-term use to prevent reliance on the medication. The short-term approach is designed to use the medication as a tool to help patients establish healthier eating patterns and lose enough weight to make physical activity easier and more sustainable. The goal is that by the time patients stop taking the medication, they will have developed the habits and lost enough weight that they can continue to progress or maintain their weight loss without pharmacological support.

Phentermine can help users lose between 5-7% of their initial body weight across a 6 month period. While this may seem modest compared to newer medications, this level of weight loss can have significant health benefits, including improvements in blood pressure, blood sugar control, cholesterol levels, and reduction in joint pain. For someone weighing 100kg, a 5-7% weight loss represents 5-7kg, which can make a meaningful difference to health and quality of life. Studies have shown that even modest weight loss can reduce the risk of developing type 2 diabetes by up to 58% in people at high risk.

At Bodyline Clinic, our doctors and nurse prescribers are regulated by the Care Quality Commission (CQC), and we have been providing Phentermine to thousands of patients within our fully supported medical weight loss programmes. Our CQC regulation means that our practices, facilities, and clinical protocols are regularly inspected to ensure they meet rigorous safety and quality standards. This regulatory oversight provides patients with confidence that they are receiving care from a legitimate, accountable healthcare provider rather than from unregulated sources that may not prioritise patient safety.

Phentermine is one of Bodyline's most commonly prescribed appetite suppressant medications and is usually tolerated well with minimal side-effects. However, those who are not eligible for Phentermine can get similar results from another oral tablet called Diethylpropion. Some patients cannot take Phentermine due to contraindications such as cardiovascular conditions, uncontrolled high blood pressure, hyperthyroidism, or interactions with other medications they're taking. In these cases, Diethylpropion offers an alternative that works through similar mechanisms but may be suitable for patients who cannot safely use Phentermine. Both medications require thorough medical assessment before prescribing to ensure patient safety.

Both Phentermine and Diethylpropion have been seen to produce incredible weight loss results in a short period of time, however it is vital they are used with clinical support. Short term weight loss can only be maintained when a person's habits have changed for the better. This is why at Bodyline, we don't simply prescribe medication and send patients away. Our medical weight loss programmes include regular check-ins with our nursing team, nutritional guidance, support with developing sustainable eating patterns, advice on increasing physical activity safely, and strategies for managing the psychological and emotional aspects of weight loss. We monitor blood pressure and other health markers throughout treatment to ensure safety and adjust treatment plans as needed.

Habit formation is the key to sustainable weight loss – and this is the case for all medical weight loss interventions, even the newest ones. Research in behavioural psychology shows that it takes consistent repetition over time to establish new habits that become automatic. During the months that patients take appetite suppressant medication, they have a window of opportunity to practice healthier eating patterns without fighting against overwhelming hunger. They can learn what appropriate portion sizes look like, discover healthy foods they enjoy, establish regular meal times, and develop strategies for managing emotional eating. When the medication is discontinued, these habits are already established, making it much easier to maintain weight loss long-term. This is why the support component of medical weight loss programmes is just as important as the medication itself.

Contact Bodyline today to find out more about our safe and effective weight loss programmes and range of treatment options.

If you're considering medical weight loss treatment, we invite you to book a consultation at Bodyline Clinic to discuss which treatment option might be most suitable for your individual circumstances. Our experienced clinical team can assess your medical history, discuss your weight loss goals, and develop a personalised treatment plan that takes into account your lifestyle, preferences, and any existing health conditions. With clinic locations across the Northwest of England in Birkenhead, Liverpool, Manchester, St Helens, Stockport, Stoke-on-Trent, and Warrington, as well as online consultations available UK-wide, accessing expert support has never been easier. Call us today on 0800 995 6036 or fill in our contact form to take the first step towards achieving your weight loss goals with professional medical support.

How a diabetes drug trial changed the world as we know it

A new class of weight loss therapies are now breaking the mould and producing completely game changing weight loss results and health outcomes, and it all started from a diabetes drug trial. The story of how GLP-1 medications transitioned from diabetes treatment to weight loss therapy is a fascinating example of how medical research can lead to unexpected breakthroughs that transform treatment landscapes. The connection between blood sugar regulation and weight management had been observed for years, but it wasn't until the development of long-acting GLP-1 agonists that the full potential of this class of medications became apparent.

Pharmaceutical and healthcare company Novo Nordisk was trialling a new type-2 diabetes treatment called semaglutide, with the purpose of controlling blood sugar levels and insulin resistance. After unprecedented weight loss results in trial participants, the marketed injectable medication called 'Ozempic' was trialled on individuals with obesity without type-2 diabetes. The researchers noticed that patients in the diabetes trials were losing significant amounts of weight as a "side effect" of the medication. This observation led to the hypothesis that if the medication could be optimised and studied specifically for weight loss in people without diabetes, it might provide a breakthrough treatment for obesity. The subsequent trials, known as the STEP trials, enrolled thousands of participants and demonstrated conclusively that semaglutide was highly effective for weight loss in people with obesity.

The results were groundbreaking – when combined with diet and exercise, users were seen to lose 15% of their initial body weight on average over a 68-week period. To put that in perspective, a 200lb adult would have lost around 30lbs – reducing the health risks of obesity and boosting their confidence in one go. What made these results particularly impressive was not just the amount of weight lost, but the consistency of the results across diverse patient populations and the fact that the weight loss was sustained as long as patients continued taking the medication. Previous weight loss medications had typically achieved much more modest results, with average weight losses in the range of 5-10% of body weight. The 15% average weight loss with semaglutide represented a step change in what was achievable with medical treatment.

These results overtook the existing weight loss injection Saxenda, approved in the UK in 2014, which contains liraglutide. Liraglutide was actually the first GLP-1 medication to be approved specifically for weight management, and it represented an important advance at the time. However, liraglutide requires daily injections and typically produces weight loss of around 5-10% of body weight, which, while clinically meaningful, is less dramatic than what can be achieved with semaglutide. The development of semaglutide built upon the foundation laid by liraglutide, demonstrating that longer-acting GLP-1 agonists with improved pharmacological properties could achieve even better results.

Ozempic's active ingredient semaglutide mimics the glucagon-like-peptide-1 hormone, known as GLP-1, which is naturally produced in the gut following mealtimes and tells our body we are full. The GLP-1 receptor agonist, semaglutide, is administered once a week by injection, and dosage is increased gradually. Understanding how GLP-1 works in the body helps explain why these medications are so effective for weight loss. GLP-1 is one of several "incretin" hormones released by the intestines in response to food intake. It has multiple effects: it stimulates insulin secretion when blood sugar is elevated, suppresses glucagon secretion (which prevents the liver from releasing too much glucose), slows gastric emptying (which prolongs the feeling of fullness after eating), and acts on areas of the brain involved in appetite regulation to reduce hunger and food cravings.

Dr Morgan Toerien, one of Bodyline's wellness practitioners explains it like this: "GLP-1s like semaglutide work for obesity because an obese individual is either not making enough of these hormones to produce that full feeling naturally, or their body is resistant to the hormones so that they need a higher dose to get the same effect. This concept is similar to insulin resistance in type 2 diabetes – the hormone is present but the body's response to it is blunted, requiring higher levels to achieve the same effect. In some cases, people with obesity may have lower baseline levels of GLP-1 production, while in others, the receptors that respond to GLP-1 may be less sensitive.

"If their body is not producing enough for them, using these therapies essentially introduces more into our bodies so that there's enough of it to do the job, make us feel fuller, and reduce our calorie intake. By providing a pharmaceutical version of GLP-1 that is present at much higher and more sustained levels than the body naturally produces, we can overcome both insufficient production and receptor resistance. The medication essentially restores normal appetite regulation in people whose systems are not functioning optimally.

"This means it doesn't matter whether you're not making enough or whether you're resistant to it; by adding more, it's restoring the natural physiological process that our bodies are meant to perform." This is an important point because it reframes these medications not as artificial interventions that override normal body processes, but rather as treatments that restore normal function in a system that has become dysregulated. This is why patients often describe that taking GLP-1 medications makes them feel "normal" around food for the first time in years – they're not experiencing artificial appetite suppression, but rather the natural satiety signals that people without obesity experience naturally.

The success of the trials meant that Novo Nordisk re-marketed the drug as 'WeGovy' and packaged it in different dosages for prescribers to titrate the medication as part of safe practice. As a result, semaglutide was approved by NICE to treat obesity in the UK for those with a BMI of above 35, or above 30 with weight health related problems. The distinction between Ozempic and Wegovy is important – while both contain semaglutide, Ozempic is licensed and marketed for type 2 diabetes treatment at doses up to 1mg weekly, while Wegovy is licensed for weight management at doses up to 2.4mg weekly. The higher dose used in Wegovy is necessary to achieve optimal weight loss results.

Both eligibility and titration are vital for patient safety, to ensure minimal side effects and potential adverse reactions. Though the medication is only a few years old, there have already been safety concerns due to black market variants being sold on social media and through unregulated online pharmacies, leading to people falling seriously ill. The most common side effects of GLP-1 medications are gastrointestinal – nausea, vomiting, diarrhoea, and constipation. These effects are usually mild to moderate and tend to diminish over time, but they can be quite unpleasant initially. Starting at a low dose and increasing gradually allows the body to adapt to the medication, significantly reducing the severity of these side effects. This is why the medication comes in several different dose strengths and why proper medical supervision during the dose escalation phase is so important.

Semaglutide should only be prescribed by regulated and registered clinicians like doctors and nurse prescribers according to NICE guidelines. These checks and balances are vital to ensure safety and best possible patient outcomes. Before prescribing semaglutide or any weight loss medication, clinicians should take a thorough medical history, assess for contraindications, check blood pressure, and discuss realistic expectations and the need for lifestyle changes alongside medication. During treatment, regular monitoring is necessary to assess response, manage side effects, and ensure patients are losing weight at a healthy rate. This level of clinical oversight simply cannot be provided through unregulated online sources or social media sellers.

More information about recognising safe providers can be found in our guide on identifying illegal slimming pens. This resource helps patients understand the warning signs of unregulated suppliers and explains why choosing a CQC-regulated provider like Bodyline is so important for safety. We've seen the consequences of people obtaining medications from unsafe sources, and we're committed to educating the public about these risks while providing a safe, legal, and medically supervised alternative.

The King Kong of weight loss injections

Semaglutide enjoyed the top spot for game-changing weight loss for some time, but it wasn't long before another medication surpassed its results and efficacy by targeting two hormones instead of one. The pharmaceutical industry had learned from the success of GLP-1 medications that targeting appetite regulation through hormonal pathways was highly effective. The logical next step was to explore whether targeting multiple pathways simultaneously could produce even better results. This led to the development of dual-agonist medications that activate both GLP-1 and GIP receptors.

Tirzepatide was also originally formulated as a diabetes treatment, but once its results produced 'unmatched' glycaemic control and weight management, it quickly followed the same route as semaglutide and was approved for obesity treatment in 2023. The development of tirzepatide represented a significant investment in understanding the interplay between different incretin hormones and how they could be harnessed for therapeutic benefit. The molecule was engineered to activate both GIP and GLP-1 receptors, with the hypothesis that this dual action would produce superior results to GLP-1 activation alone.

Labelled as Mounjaro, tirzepatide has a dual-acting mechanism, mimicking two hormones to increase the likelihood of weight loss. Alongside GLP-1 receptor agonists, tirzepatide also mimics gastric inhibitory polypeptide (GIP), which is also known as glucose-dependent insulinotropic polypeptide. Like Ozempic and WeGovy, it comes in the form of a once-weekly injectable pen. GIP is another incretin hormone that is released from the intestines after eating. Historically, the role of GIP in weight regulation was less well understood than GLP-1, and some researchers even thought that blocking GIP might be beneficial for weight loss. However, the success of tirzepatide has demonstrated that activating GIP receptors, when done in combination with GLP-1 activation, actually enhances weight loss.

Tirzepatide was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) late 2023 and is to be titrated and used within a supported programme of diet and exercise. The approval process involved rigorous evaluation of clinical trial data demonstrating both the efficacy and safety of the medication. Like semaglutide, tirzepatide must be started at a low dose and gradually increased to minimise side effects and allow the body to adapt. The medication is available in several dose strengths, with the maximum dose being 15mg weekly, compared to 2.4mg weekly for semaglutide.

The GIP/GLP-1 combination has shown weight loss results far surpassing its opponents. Clinical trials reported participants saw an average 20% body weight reduction when paired with diet and exercise. For a starting weight of 200lbs, that's a loss of 40lbs. The SURMOUNT trials, which studied tirzepatide for weight management, showed that at the highest dose, participants lost an average of 20.9% of their body weight over 72 weeks. Even more impressively, over half of participants lost at least 20% of their body weight, and more than a third lost at least 25%. These results approach what has traditionally only been achievable with bariatric surgery, but without the surgical risks and with the reversibility that comes with medical treatment.

But why does it work so much better? Dr Morgan Toerien explains: "By combining the two hormones, we can treat a broader base of deficiencies. We're not just working on one pathway but working on two pathways. The dual mechanism means that even if someone has particular resistance to one of the hormones, the other pathway can still contribute to the therapeutic effect. This increases the likelihood that the medication will be effective for any given individual.

"Think of it a little bit like trying to fill a paddling pool with one hose or trying to fill it with two hoses. If you've got two different hoses, your chances of getting it filled quicker are better. With tirzepatide, patients can hedge their bets in terms of whichever one of their hormones is more likely to be deficient or more likely to be resistant to, and one will be in the package. This analogy helps patients understand that having two mechanisms of action provides redundancy and enhanced effectiveness.

"However, the two things together also have a synergistic effect. The effect is magnified, and not just a duplication. It isn't just that you've got two hormones, therefore, you're twice as likely to lose weight. You're likely to lose much more than twice as much." This synergy appears to occur because GIP and GLP-1 interact with each other's pathways in complex ways. GIP may enhance the effects of GLP-1 on appetite centers in the brain, while GLP-1 may enhance the metabolic effects of GIP. The result is that the combined effect is greater than the sum of the individual effects – a true synergy that explains why tirzepatide produces such impressive results.

Mounjaro has been increasing in popularity, and at Bodyline we have seen a significant uptick in our medical weight loss programme patients who are eligible and opting in for this injectable medication. Many patients are attracted to Mounjaro because of the superior weight loss results seen in clinical trials, and we've found that patients who have tried semaglutide but plateaued or didn't achieve their desired results often do very well when switched to tirzepatide. However, it's important to note that Mounjaro is not suitable for everyone, and the choice between different medications should be made in consultation with a qualified healthcare provider who can assess individual circumstances and medical history.

The unparalleled weight loss results meant the medication was described as the 'King Kong' of weight loss medication, and as social media users document their progress, its popularity is ever growing. The nickname "King Kong" captures the sense that this medication is more powerful than what came before it. However, with this power comes the need for even more careful medical supervision. The more effective a medication is, the more important it becomes to ensure it's used appropriately, with proper monitoring, and in patients who will benefit from it. At Bodyline, we ensure that all patients starting on Mounjaro receive comprehensive education about the medication, clear guidance on managing side effects, and regular follow-up appointments to monitor progress and adjust treatment as needed.

Looking Ahead to the Future of Weight Loss

From earlier appetite suppressants to treatments targeting more than one hormone pathway, the history of weight loss medication shows how our understanding of obesity has developed. Looking ahead, the focus should include making treatment easier to access, understanding long-term outcomes and helping people maintain their progress.

For anyone considering medical weight loss, the headlines only tell part of the story. Your medical history, existing medications, preferences and experience of previous treatments all matter when discussing your options. Clinical trial averages cannot predict exactly how much weight an individual will lose.

Exploring Your Options with Bodyline Clinic

With so much information about weight loss injections and tablets available, knowing where to start can feel overwhelming. A conversation with a qualified clinician gives you the opportunity to ask questions, understand potential benefits and risks, and explore whether treatment could be appropriate for you.

At Bodyline Clinic, our team can discuss your weight management goals and assess your suitability for treatment, alongside nutritional advice and ongoing support.

To find out more about our medically supervised weight management programmes, contact Bodyline Clinic and take the first step towards understanding your options.